ArticleScience advances2018

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Stephen T Durant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.